Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: An AIDS malignancy consortium study

Journal of Clinical Oncology

Volumn 24, Issue 9, 2006, Pages 1389-1394

  Dezube, Bruce J ^a   Krown, Susan E ^a   Lee, Jeannette Y ^a   Bauer, Kenneth S ^a   Aboulafia, David M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ANTHRACYCLINE DERIVATIVE; ANTIRETROVIRUS AGENT; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; TETRACYCLINE CMT 3; TETRACYCLINE CMT-3; TETRACYCLINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANEMIA; ARTICLE; BRAIN ISCHEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELUSION; DESQUAMATION; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ENZYME BLOOD LEVEL; FEBRILE NEUTROPENIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MOUTH PAIN; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; WOUND INFECTION; BLOOD; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; ADULT; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; SARCOMA, KAPOSI; TETRACYCLINES; TREATMENT OUTCOME;

EID: 33645454133     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.2614     Document Type: Article

References (23)

1. Aoki Y, Jaffe ES, Chang Y, et al: Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93:4034-4043, 1999
2. Martin JN, Osmond DH: Kaposi's sarcoma-associated herpesvirus and sexual transmission of cancer risk. Curr Opin Oncol 11:508-515, 1999
3. Mesri EA: Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpes-virus/HHV8: A missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Blood 93:4031-4033, 1999
4. Matrisian LM: The matrix-degrading metalloproteinases. Bioessays 14:455-463, 1992
5. Bernhard EJ, Gruber SB, Muschel RJ: Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 91:4293-4297, 1994
6. Kawamata H, Kameyama S, Kawai K, et al: Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. Int J Cancer 63:568-575, 1995
7. Ray JM, Stetler-Stevenson WG: Gelatinase A activity directly modulates melanoma cell adhesion and spreading. Embo J 14:908-917, 1995
8. Meade-Tollin LC, Way D, Witte MH: Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells. Acta Histochem 101:305-316, 1999
9. Rosano L, Spinella F, Di Castro V, et al: Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo. Am J Pathol 163:753-762, 2003
10. Toschi E, Barillari G, Sgadari C, et al: Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Mol Biol Cell 12:2934-2946, 2001
11. Golub LM, Lee HM, Ryan ME, et al: Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 12:12-26, 1998
12. Golub LM, Ramamurthy NS, McNamara TF, et al: Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 2:297-321, 1991
13. Hidalgo M, Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178-193, 2001
14. Lokeshwar BL, Selzer MG, Zhu BQ, et al: Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer 98:297-309, 2002
15. Seftor RE, Seftor EA, De Larco JE, et al: Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis 16:217-225, 1998
16. Cianfrocca M, Cooley TP, Lee JY, et al: Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: A phase I AIDS malignancy consortium study. J Clin Oncol 20:153-159, 2002
17. Krown SE, Metroka C, Wernz JC: Kaposi's sarcoma in the acquired immune deficiency syndrome: A proposal for uniform evaluation, response, and staging criteria - AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 7:1201-1207, 1989
18. Miles SA, Dezube BJ, Lee JY, et al: Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 16:421-429, 2002
19. Northfelt DW, Dezube BJ, Thommes JA, et al: Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15:653-659, 1997
20. Rosenthal E, Poizot-Martin I, Saint-Marc T, et al: Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. Am J Clin Oncol 25:57-59, 2002
21. Noy A, Scadden DT, Lee J, et al: Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: From the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol 23:990-998, 2005
22. Zink MC, Uhrlaub J, DeWitt J, et al: Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 293:2003-2011, 2005
23. Wieand HS: Randomized phase II trials: What does randomization gain? J Clin Oncol 23:1794-1795, 2005